Craig Viti
NPI 1912973256 · Specialist · Pittsburgh, PA
Enrolled with Medicare as Practitioner - Pulmonary Disease · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1912973256
- Entity type
- Individual
- Primary specialty
- SpecialistOther Service Providers
- Sex
- Male
- Sole proprietor
- No
- License
- MD042351L (PA)
Specialties & taxonomies
Other Service Providers
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
20 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)25% of score
337 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Established Patient Office Or Other Outpatient Visit With High Level of Medical Decision Making, If Using Time, 40 Minutes Or More99215 | 75 | $140 |
| Critical Care, First 30-74 Minutes99291 | 47 | $208 |
| Test to Determine Lung Volumes Using Sensors94726 | 34 | $12 |
| Test to Examine How Well the Lungs Exchange Gases94729 | 34 | $9 |
| Subsequent Hospital Care With Moderate Levelof Medical Decision Making, If Using Time, at Least 50 Minutes99233 | 31 | $116 |
| Test to Measure Expiratory Airflow and Volume Changes Before and After Medication Administration94060 | 20 | $10 |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 19 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Fluticasone/Umeclidin/Vilanterbrand: Trelegy Ellipta | 301 | 58 |
| Umeclidinium Brm/Vilanterol Trbrand: Anoro Ellipta | 133 | 32 |
| Albuterol Sulfatebrand: Albuterol Sulfate Hfa | 117 | 35 |
| Fluticasone/Vilanterolbrand: Breo Ellipta | 116 | 25 |
| Montelukast Sodium | 68 | 11 |
| Albuterol Sulfatebrand: Ventolin Hfa | 52 |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$234 across 7 records (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2006-02-27
- Last updated
- 2021-05-24
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.